Overview

Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients

Status:
Completed

Trial end date:
2006-09-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the effect of conversion from calcineurin inhibitor based therapy to Rapamune based therapy in patients with mild to moderate renal insufficiency.

Phase:

Phase 3

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Calcineurin Inhibitors
Cyclosporine
Cyclosporins
Sirolimus
Tacrolimus